Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxyprogesterone - Lipocine

Drug Profile

Hydroxyprogesterone - Lipocine

Alternative Names: 17-alpha hydroxyprogesterone caproate; Hydroxyprogesterone caproate - Lipocine; Hydroxyprogesterone caproate oral - Lipocine; LPCN-1107; Oral hydroxyprogesterone caproate - Lipocine

Latest Information Update: 14 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipocine
  • Class Hormones; Pregnenediones; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preterm labour
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Preterm labour

Most Recent Events

  • 08 Aug 2022 Hydroxyprogesterone - Lipocine is available for licensing as of 08 Aug 2022. https://www.lipocine.com/partnering/ 9365273
  • 27 Jul 2021 Lipocine completes a phase II trial in Preterm labour (Prevention) (Lipocine website, July 2021)
  • 05 Apr 2021 Hydroxyprogesterone caproate oral is still in phase II trials for Preterm labour (Prevention) in USA (PO) (Lipocine pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top